CN117003894B - 一种含有IL-2和Fc的gE融合蛋白及其制备方法和应用 - Google Patents
一种含有IL-2和Fc的gE融合蛋白及其制备方法和应用 Download PDFInfo
- Publication number
- CN117003894B CN117003894B CN202310999194.XA CN202310999194A CN117003894B CN 117003894 B CN117003894 B CN 117003894B CN 202310999194 A CN202310999194 A CN 202310999194A CN 117003894 B CN117003894 B CN 117003894B
- Authority
- CN
- China
- Prior art keywords
- fusion protein
- adjuvant
- vaccine
- varicella
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 67
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 65
- 108010002350 Interleukin-2 Proteins 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 239000002671 adjuvant Substances 0.000 claims abstract description 48
- 229960005486 vaccine Drugs 0.000 claims abstract description 39
- 102000000588 Interleukin-2 Human genes 0.000 claims abstract description 38
- 239000000427 antigen Substances 0.000 claims abstract description 10
- 102000036639 antigens Human genes 0.000 claims abstract description 10
- 108091007433 antigens Proteins 0.000 claims abstract description 10
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims abstract description 7
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 7
- 102000055277 human IL2 Human genes 0.000 claims abstract description 7
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 43
- 239000002502 liposome Substances 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 239000013604 expression vector Substances 0.000 claims description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 229940124742 varicella zoster vaccine Drugs 0.000 claims description 12
- 230000007935 neutral effect Effects 0.000 claims description 9
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 9
- 229930182490 saponin Natural products 0.000 claims description 9
- 150000007949 saponins Chemical class 0.000 claims description 9
- 238000012216 screening Methods 0.000 claims description 8
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 5
- 239000013612 plasmid Substances 0.000 claims description 4
- 101900123149 Varicella-zoster virus Envelope glycoprotein E Proteins 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 2
- 125000000129 anionic group Chemical group 0.000 claims description 2
- 108010083912 bleomycin N-acetyltransferase Proteins 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 238000010367 cloning Methods 0.000 claims description 2
- 239000007908 nanoemulsion Substances 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims 1
- 229940001007 aluminium phosphate Drugs 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 abstract description 25
- 208000007514 Herpes zoster Diseases 0.000 abstract description 17
- 230000005847 immunogenicity Effects 0.000 abstract description 13
- 238000007086 side reaction Methods 0.000 abstract description 10
- 101000807236 Human cytomegalovirus (strain AD169) Membrane glycoprotein US3 Proteins 0.000 abstract description 6
- 229940023143 protein vaccine Drugs 0.000 abstract description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 108010075254 C-Peptide Proteins 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000007969 cellular immunity Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000012460 protein solution Substances 0.000 description 5
- 238000003259 recombinant expression Methods 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 229940031626 subunit vaccine Drugs 0.000 description 5
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- AVWQQPYHYQKEIZ-UHFFFAOYSA-K trisodium;2-dodecylbenzenesulfonate;3-dodecylbenzenesulfonate;4-dodecylbenzenesulfonate Chemical compound [Na+].[Na+].[Na+].CCCCCCCCCCCCC1=CC=C(S([O-])(=O)=O)C=C1.CCCCCCCCCCCCC1=CC=CC(S([O-])(=O)=O)=C1.CCCCCCCCCCCCC1=CC=CC=C1S([O-])(=O)=O AVWQQPYHYQKEIZ-UHFFFAOYSA-K 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229940124925 Zostavax Drugs 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241001539473 Euphoria Species 0.000 description 2
- 206010015535 Euphoric mood Diseases 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000001670 anatto Substances 0.000 description 2
- 239000000337 buffer salt Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000012526 feed medium Substances 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- RAFGELQLHMBRHD-VFYVRILKSA-N Bixin Natural products COC(=O)C=CC(=C/C=C/C(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C(=O)O)/C)C RAFGELQLHMBRHD-VFYVRILKSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 101100208253 Dictyostelium discoideum tspA gene Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 201000004328 Pulpitis Diseases 0.000 description 1
- 206010037464 Pulpitis dental Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 229940124863 Varicella-zoster virus vaccine Drugs 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- RAFGELQLHMBRHD-UHFFFAOYSA-N alpha-Fuc-(1-2)-beta-Gal-(1-3)-(beta-GlcNAc-(1-6))-GalNAc-ol Natural products COC(=O)C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC(O)=O RAFGELQLHMBRHD-UHFFFAOYSA-N 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000012665 annatto Nutrition 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- RAFGELQLHMBRHD-SLEZCNMESA-N bixin Chemical compound COC(=O)\C=C\C(\C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C(O)=O RAFGELQLHMBRHD-SLEZCNMESA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明公开了一种含有IL‑2和Fc的gE融合蛋白及其制备方法和应用，gE融合蛋白包括水痘‑带状疱疹病毒（VZV）糖蛋白E（gE）胞外区段、人白细胞介素2序列（IL‑2）和人免疫球蛋白G1的Fc段（Fc）。解决了现有技术中基因工程重组带状疱疹疫苗抗原的免疫原性较弱和疫苗副反应严重的技术问题。本发明中gE融合蛋白（IL2‑gE‑Fc）抗原具有优良的免疫原性，因此配制gE融合蛋白疫苗时，可减少佐剂的种类和用量，大大降低了疫苗的副反应；同时，该gE融合蛋白疫苗的免疫原性优于已上市重组带状疱疹疫苗。总之，与已上市重组带状疱疹疫苗相比，该gE融合蛋白疫苗副反应更低，免疫原性更好，具有良好的临床应用潜力。
Description
技术领域
本发明涉及生物医学领域，具体涉及一种含有IL-2和Fc的gE融合蛋白及其制备方法和应用。
背景技术
水痘-带状疱疹病毒(varicella zoster virus，VZV)又称3型人疱疹病毒，是一种人类α疱疹病毒。水痘-带状疱疹病毒在正常人群中的原发性感染，会在儿童时期导致水痘。感染VZV后，病毒会于人体神经节内潜伏，当各种原因导致的免疫力下降时，病毒会再度被激活并大量复制，会导致带状疱疹(herpes zoster，HZ)，并常常伴随有带状疱疹后遗神经痛(Post-herpetic neuralgia，PHN)。在免疫功能受损的人群中VZV感染可能伴有髓炎、脑髓炎等严重的并发症。VZV的基因组大小约为125kb，编码约69种蛋白，编码的糖蛋白有8个，包括gB、gC、gE、gH、gI、gK、gL、gM。其中糖蛋白E(glycoprotein E，gE)是宿主免疫系统识别的主要糖蛋白，也是病毒包膜和感染细胞膜上抗原性最强、含量最丰富的糖蛋白，同时它还广泛存在于在VZV颗粒的表面和宿主细胞的细胞膜和胞质中，能诱导细胞免疫和体液免疫。
水痘-带状疱疹病毒的传染性及强，主要通过空气飞沫和直接接触传播，据报道全世界50岁以上成人中约有90％的血清VZV检测呈阳性。儿童感染VZV后会引起发热，并出现周身性红色斑丘疹、疱疹和痂疹，有自限性。随着年龄增长，机体免疫力下降，带状疱疹的发病率呈逐渐增加，随着现在生活节奏加快，生活压力增加，带状疱疹的发病呈现年轻化的趋势。水痘-带状疱疹的发病严重影响人们的生活质量，特别是PHN的存在。PHN是带状疱疹最常见的后遗症，在带状疱疹中的发生率为10％～30％，疼痛可持续数月至数年，最长可达10年。
默沙东公司高剂量(约20000PFU)减毒活疫苗产品Zostavax，2005年被批准在50岁以上成人中用于预防带状疱疹，疫苗的不良反应主要以接种部位的疼痛、红斑和肿胀为主，大规模临床实验证明，在50-59岁年龄阶段人群中，疫苗的保护率为69.8％，大于60岁以上人群中保护率为51％，随年龄的增加保护率逐渐降低，≥80岁以上人群中保护率只有18％。在预防PHN方面，对≥60岁以上人群，疫苗保护率为39％。有文献报道Zostavax疫苗接种5～8年后疫苗效力持续下降，超过8年后统计学上不在显著。国内目前有长春百克的带状疱疹减毒活疫苗于2023年02月获批上市。
葛兰素史克公司的佐剂带状疱疹亚单位疫苗Shingrix于2017年经FDA批准上市，用于在50岁以上成人中预防带状疱疹。该疫苗有两部分组成，一是由CHO细胞表达的截短VZV糖蛋白E，一是AS01B佐剂系统。相对于减毒活疫苗Zostavax，佐剂亚单位疫苗Shingrix的副反应更严重，疫苗接种后7天内，试验组和安慰剂组受试者至少1种征集性症状的发生率分别为84.5％和33.7％，至少1种3级征集性AE的发生率分别为16.0％和2.5％。临床实验证明，该疫苗在≥50岁的受试者中，对HZ的总体保护率为97.16％。按50-59岁、60-69岁、≥70岁分层分析，本品对HZ的保护率在各年龄层相当，其中50-59岁为96.57％，60-69岁为97.36％，≥70岁为97.93％。在预防PHN反面，在≥50岁正常人群中，Shingrix可使PHN的发病率降低91.2％。在≥70岁正常人群中，降低88.8％。对疫苗效力的持续研究表明，疫苗的有效性可持续10年以上。AS01B佐剂系统含有3D-MPL、QS-21以及磷脂酰胆碱、胆固醇等成分，能显著提高疫苗的效力，但它有个极大的缺点是副反应程度和发生率都高。
公布号为CN110343722的专利公布了一种重组表达水痘-带状疱疹病毒v-Oka株截短型糖蛋白E的方法，该方法将截短的gE蛋白基因导入杆状病毒中，利用重构的杆状病毒感染昆虫细胞表达可溶性的gE蛋白。该方法易于筛选，批间稳定，但用昆虫细胞表达的蛋白相较于哺乳动物细胞糖基化方面有较大差异，且单独的蛋白并不能有效激活人体的体液及细胞免疫功能。
公布号为CN112870344专利公开了一种重组水痘带状疱疹疫苗的制备方法，该方法在CHO细胞中表达截短gE和IgG抗体Fc段的融合蛋白gE-Fc。重组蛋白经一系列色谱纯化，并经过病毒灭活后，得到了高度纯化的融合蛋白质。gE-Fc融合蛋白配伍铝佐剂的免疫原性较差，其免疫动物只能刺激产生较低水平的gE结合抗体和gE特异性细胞免疫水平。
目前被批准用于预防VZV感染的疫苗有两种，一种是VZV减毒活疫苗(Oka株)，低剂量用于预防儿童水痘，高剂量用于预防带状疱疹；一种是配合佐剂系统使用的基因工程重组亚单位疫苗。临床实验证明减毒活疫苗的副反应较小，但是保护效率及保护持久性较低，疫苗生产工艺复杂，放大生产受限；配合佐剂系统的重组亚单位疫苗，保护效率好持久性高，但疫苗副反应及强，佐剂系统中3D-MPL来源于沙门氏菌的脂多糖的脱毒产物，产量低，疫苗成本高。大量研究证明，细胞免疫功能在VZV感染中发挥着极其重要的作用，文献报道的其他基因工程重组亚单位疫苗，要么因抗原设计原因导致的抗原免疫原性较弱，要么是因为使用的佐剂系统为传统铝佐剂，细胞免疫功能弱。因此在预防水痘带状疱疹发病方面较弱。
发明内容
本发明的目的在于提供一种含有IL-2和Fc的gE融合蛋白及其制备方法和应用，将截短的gE(去除gE的跨膜区域和膜内序列)、人白细胞介素2(IL2)和I型人免疫球蛋白γ(IgG1)的Fc段(Fc)核苷酸序列用linker连接，插入表达载体中，转染哺乳动物细胞CHO K1，表达gE融合蛋白IL2-gE-Fc。该gE融合蛋白IL2-gE-Fc具有优良的免疫原性，配合XA401复合佐剂(QS-21+中性脂质体)使用，可诱导产生比已上市重组带状疱疹疫苗更高的体液免疫和细胞免疫水平。
为实现上述目的，本发明提供了以下技术方案：
本发明提供的一种含有IL-2和Fc的gE融合蛋白，所述融合蛋白包括水痘-带状疱疹病毒(VZV)糖蛋白E(gE)胞外区段、人白细胞介素2序列(IL-2)和人免疫球蛋白G1的Fc段(Fc)，编码含有gE、IL-2、Fc的融合蛋白的基因序列能够在基因工程化细胞中表达含有IL-2和Fc的gE融合蛋白。
进一步的，所述含有IL-2和Fc的gE融合蛋白其氨基酸序列组合方式包括IL-2-gE-Fc、IL-2-Fc-gE、gE-Fc-IL-2、Fc-gE-IL-2、Fc-IL-2-gE、gE-IL-2-Fc；所述gE、IL-2、Fc之间通过连接肽连接，所述连接肽为GGS和/或GGGS和/或GGGGS和/或GSGSG连接肽。
进一步的，所述含有IL-2和Fc的gE融合蛋白其基酸序列组合方式优选为IL-2-gE-Fc，所述IL-2-gE-Fc的氨基酸序列如SEQ ID NO.7所示。
一种水痘-带状疱疹疫苗，包括抗原和佐剂，所述抗原为含有IL-2和Fc的gE融合蛋白。
进一步的，所述的水痘-带状疱疹疫苗在预防或改善水痘-带状疱疹中的应用。
进一步的，所述佐剂为氢氧化铝佐剂、磷酸铝佐剂、含有皂素的中性脂质体佐剂、含有皂素的阳离子脂质体佐剂、含有皂素的阴离子脂质体佐剂，CpG佐剂、纳米乳剂、含有3D-MPL的佐剂中的任意一种或任意多种组合使用。
进一步的，所述水痘-带状疱疹病毒的疫苗的每个剂量单位中含有融合蛋白5～200μg，优选的，每个剂量单位中含有融合蛋白10～100μg，更优选的，每个剂量单位中含有融合蛋白20～80μg。
一种水痘-带状疱疹疫苗的制备方法，包括以下步骤：
S1、培养基因工程化细胞，在基因工程化细胞内表达含有IL-2和Fc的gE融合蛋白，所述基因工程化细胞为CHO细胞；
S2、分离含有IL-2和Fc的gE融合蛋白；
S3、佐剂制备；
S4、疫苗配制。
进一步的，所述S1包括：
S11、将含有IL-2和Fc的gE融合蛋白的基因克隆入表达载体中；
S12、将S11所得的表达载体转化至基因工程化细胞中；
S13、通过迷你细胞群的筛选和单克隆筛选，获得稳定表达含有IL-2和Fc的gE融合蛋白的细胞株；
S14、使用S13所得的细胞株进行表达，获得含有IL-2和Fc的gE融合蛋白。
进一步的，所述CHO细胞优选为CHO-K1细胞。
进一步的，所述表达载体为携带GS筛选系统和/或携带博莱霉素抗性基因的质粒表达载体。
基于上述技术方案，本发明实施例至少可以产生如下技术效果：
(1)本发明将将截短的gE(去除gE的跨膜区域和膜内序列；gE)、人白细胞介素2(IL2)和I型人免疫球蛋白γ(IgG1)的Fc段(Fc)核苷酸序列用linker连接，插入表达载体中，转染哺乳动物细胞CHOK1，表达gE融合蛋白IL2-gE-Fc。
(2)本发明提供的含有IL-2和Fc的gE融合蛋白具有优良的免疫原性，其和XA401复合佐剂配制的疫苗比欣的免疫原性更优。gE融合蛋白和复合佐剂XA401(含有QS-21和中性脂质体)配制成的疫苗(gE融合蛋白作为抗原；QS-21和中性脂质体组成的XA401复合佐剂作为佐剂)的免疫原性优于欣/>(gE作为抗原；QS-21、MPL、中性脂质体组成的AS01佐剂系统作为佐剂)。
QS-21(皂皮树皂苷QS-21)和中性脂质体(DOPC和胆固醇)含量均与GSK公司的欣安中AS01B佐剂系统一致的条件下，不含MPLA(单磷酰脂质A)免疫刺激剂的XA401复合佐剂配制的gE融合蛋白疫苗的免疫原性优于欣/>(含有gE抗原；QS-21、MPL、中性脂质体组成的AS01B佐剂系统)，表明了gE融合蛋白具有优良的免疫原性。
(3)本发明提供的重组水痘-带状疱疹疫苗的XA401复合佐剂具有优良的安全性，其比欣AS01佐剂系统的副反应发生率低。XA401复合佐剂主要成分为QS-21和中性脂质体，不含有生产工艺复杂，产量低，副反应高的3D-MPL成分，因此，大大降低了疫苗在临床使用中的副反应发生率。
附图说明
图1是本发明实施例表达载体PXNM3.0的结构图；
图2是gE融合蛋白表达载体IL2-gE-Fc-PXNM3.0的结构图；
图3是本发明实施例两次免疫gE蛋白特异性血清GMT效价图；
图4是本发明实施例gE特异性的CD4+T细胞反应图。
具体实施方式
下面将结合本发明实施例中的附图；对本发明实施例中的技术方案进行清楚、完整地描述；显然，所描述的实施例仅仅是本发明一部分实施例；而不是全部的实施例，基于本发明中的实施例；本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其它实施例都属于本发明保护的范围。
一种含有IL-2和Fc的gE融合蛋白，所述融合蛋白包括水痘-带状疱疹病毒(VZV)糖蛋白E(gE)胞外区段、人白细胞介素2序列(IL-2)和人免疫球蛋白G1的Fc段(Fc)，编码gE、IL-2、Fc的基因序列能够在基因工程化细胞中表达含有IL-2和Fc的gE融合蛋白。
所述含有IL-2和Fc的gE融合蛋白其氨基酸序列组合方式包括IL-2-gE-Fc、IL-2-Fc-gE、gE-Fc-IL-2、Fc-gE-IL-2、Fc-IL-2-gE、gE-IL-2-Fc；所述gE、IL-2、Fc之间通过连接肽连接，所述连接肽为GGS和/或GGGS和/或GGGGS和/或GSGSG连接肽。
所述含有IL-2和Fc的gE融合蛋白其基酸序列组合方式优选为IL-2-gE-Fc，所述IL-2-gE-Fc的氨基酸序列如SEQ ID NO.7所示。
涉及到的序列如下：
编码水痘-带状疱疹病毒(VZV)糖蛋白E(gE)胞外区段的基因序列记为gE的核酸序列，如序列表SEQ ID NO.1所示；
编码人白细胞介素2序列记为IL-2的核酸序列，如序列表SEQ ID NO.2所示；
编码人免疫球蛋白G1的Fc段记为Fc的核酸序列，如序列表SEQ ID NO.3所示；
gE的氨基酸序列如序列表SEQ ID NO.4所示；
IL-2的氨基酸序列如序列表SEQ ID NO.5所示；
Fc的氨基酸序列如序列表SEQ ID NO.6所示；
IL-2-gE-Fc的氨基酸序列如SEQ ID NO.7所示；
IL-2-gE-Fc的核酸序列如SEQ ID NO.8所示；
S1、融合蛋白密码子优化与全基因合成
对融合蛋白的基因进行密码子优化：避开常用的酶切位点；根据CHO细胞中密码子的偏好性，用频率高的密码子替代频率低的同义密码子，控制稀有密码子；控制序列中的GC含量在40％～60％，以提高mRNA的转录效率，同时避免高GC含量影响mRNA二级结构，进而影响翻译效率。在优化后的序列前面加上信号肽序列；序列的上游引入HindⅢ酶切位点，序列下游加入终止密码子及BamHⅠ酶切位点，进行核苷酸序列的全基因组合成。
S2、融合蛋白表达质粒的构建
含有全基因合成序列的克隆载体转化DH5α感受态细菌，然后大量扩增，提质粒后将克隆载体用限制性内切酶HindⅢ和BamHⅠ双酶切，同时用限制性内切酶HindⅢ和BamHⅠ双酶切表达载体pXNM3.0(如图1所示)。双酶切的克隆载体切胶回收融合蛋白基因部分，表达载体切胶回收骨架部分。二者用T4酶连接后转化DH5α感受态细菌，涂布含有氨苄抗性的平板进行筛选，阳性菌落挑斑扩增提质粒，然后用HindⅢ和BamHⅠ双酶切鉴定，正确的重组表达载体测序验证。
S3、稳转细胞株构建
鉴定正确的重组表达载体，增菌后大量提质粒，用Pvu I单酶切重组表达载体，切胶回收酶切线性化的载体，过滤除菌后待用。CHO-K1细胞复苏后连续传代两次以上，细胞活率大于95％时用于电转化。在洁净工作台中，向4mm电转杯内加入0.6ml的细胞悬浮液(约1×107个细胞)，200ul线性化后的重组表达载体(约50μg)，设置电转条件为电压为300V，电容900μF。电转结束后将细胞转移至含有30ml CD CHO培养基的细胞摇瓶中，37℃，5％二氧化碳浓度，125rpm条件下培养24小时。100g离心电转后细胞悬液10分钟，弃去上清，用含25μM MSX和200μg/ml博来霉素的CD CHO培养基重悬细胞，然后接种至24空板中，培养3周后用ELISA方法检测表达量，表达量高的3个细胞孔混合后用有限稀释法接种96孔板进行单克隆筛选，用单细胞成像设备在第0、1、2、3、7、15天拍照。15天后用ELISA方法检测表达量，表达量高的3株细胞进行冻存。稳定性研究后确定用于疫苗制备的细胞株，然后建立两级细胞库。
S4、目的产物表达
用OPM-CHO CDP9培养基复苏一只冻存的工作种子，在摇瓶中逐级放大，最后转移进5L的生物反应器内进行培养，接种密度为0.8×106cells/ml，设定培养参数为温度37℃、pH7.0、转速150r/min、溶解氧浓度40％。每日取样检测细胞活率、密度、乳酸含量、葡萄糖含量，培养至第3天，活细胞密度达到3×106cells/ml时加入补料培养基CDF18和CDF26，分别接入250ml和25ml。然后每隔1天加入相同体积的补料培养基。维持培养液中的葡萄糖含量在2g/L以上，当低于此浓度时补加葡萄糖浓度至4g/L。培养15天左右，当细胞活率低至70％时，终止培养。深层滤器过滤去除细胞及细胞碎片，收集细胞培养物上清液。
S5、融合蛋白纯化
细胞培养物上清调节pH至7.5，用pH7.5含150mM氯化钠的40mM PB缓冲液平衡亲和层析protein A至紫外吸收基线水平，pH稳定，然后将细胞上清液过柱，用相同平衡缓冲液平衡至紫外吸收基线水平后，pH3.0～4.0的乙酸-乙酸钠缓冲液，洗脱目的物。纯化产物低pH灭活(pH 3.0～4.0，18～25℃放置60min)，灭活后产物加入1M硫酸铵并调节pH至7.5，用pH7.5 50mM PB缓冲液+1M硫酸铵缓冲液平衡疏水层析柱Capto Phenyl ImpRes至紫外吸收基线水平，pH稳定，然后将灭活液过柱，相同缓冲液平衡层析柱，最后用pH7.550mM PB缓冲液线性洗脱目的物。疏水纯化产物经分子筛色谱Sephacryl S-300High Resolution分子筛色谱纯化并换液，获得纯化后的蛋白。纯化后蛋白经15nm滤器纳滤及0.22μm滤膜除菌过滤后获得疫苗原液。
S6、疫苗配制
(1)脂质体的制备(乙醇注入法；100ml体积，DOPC和胆固醇浓度分别为4mg/ml和1mg/ml)：分别称取400mgDOPC和100mg胆固醇；然后将DOPC和胆固醇完全溶于10ml无水乙醇，并混合均匀，即为有机相；将10ml有机相注入90ml的10mM PBS缓冲盐溶液(pH为7.0)中，制成脂质体初乳；再使用高压微射流均质机整粒至脂质体粒径为100nm左右；然后，通过透析方法去除乙醇；最后使用0.22μm除菌滤器过滤除菌，即为脂质体成品；
(2)佐剂的配制：取5ml脂质体，加入1ml皂苷QS-21溶液(浓度为1mg/ml)，并搅拌均匀，即为佐剂；
(3)疫苗的配制(10ml体积；gE目标浓度为100μg/ml；免疫增强剂皂苷QS-21为100μg/ml；脂质体成分：DOPC和胆固醇分别为2mg/ml和0.5mg/ml)
向佐剂中加入gE融合蛋白溶液，再使用10mM PBS缓冲盐溶液(pH为7.0)补足总体积至10ml，并搅拌均匀，即为gE融合蛋白佐剂疫苗。
加入gE融合蛋白溶液体积(ml)计算公式为：加入gE融合蛋白的质量(μg)/gE融合蛋白溶液的蛋白浓度(μg/ml)＝gE融合蛋白理论分子量*疫苗中gE目标浓度(μg/ml)*疫苗体积(ml)/[gE理论分子量*gE融合蛋白溶液的蛋白浓度(μg/ml)]＝gE融合蛋白理论分子量*100*10/(gE理论分子量*gE融合蛋白溶液的蛋白浓度)。
IL-2-gE-Fc的氨基酸序列如序列表SEQ ID NO.7所示。
S7、疫苗免疫动物
实验动物为6-8周龄的C57BL/6雌性小鼠；动物免疫及饲养在无特定病原体条件下进行。为模拟在自然环境中水痘-带状疱疹病毒的感染，在进行候选疫苗免疫前35天，用水痘-带状疱疹病毒(包含不少于3.3lg PFU活病毒，0.5ml)颈部皮下预敏免疫小鼠。在第0天和28天，腿部肌肉注射候选疫苗，注射剂量为每只小鼠50ul。在二免后28天采用眼球取血法采血，采血后处死小鼠。采集好的全血2～8℃下静置过夜，第二天3000rpm离心30min,吸取顶部血清。用间接ELISA法测小鼠血清效价，并计算GMT值。小鼠脾脏分离脾脏细胞，用胞内细胞因子染色法检测gE特异性分泌INF-γ和IL-2的CD4+T细胞数量，评价细胞免疫水平。
疫苗免疫原性分析
(1)血清中gE蛋白结合抗体检测
利用间接ELISA的方式检测所有个体小鼠二免后28天血清样本中的总gE特异性抗体。流程为用碳酸盐缓冲液将gE蛋白包被至96孔板中，包被量为500ng/孔，4℃包被过夜，用含BSA的TPBS溶液封闭，TPBS溶液洗板3次，然后所有个体小鼠血清按不同稀释度稀释后，加入孔板中，37℃孵育1小时，TPBS溶液洗板3次，然后用HRP标记的羊抗鼠二抗37℃孵育1小时，TPBS溶液洗板3次后用TMB显色液显色10min，加入0.2M硫酸终止反应，酶标仪读取OD450处数值。以一免前血清混合样品的读数的3倍作为Cut-Off值，判定免疫后血清效价，一免和二免后gE结合抗体比较如图3所示。
(2)胞内细胞因子流式细胞仪检测
二免后28天，试验小鼠取脾脏，制备脾单细胞悬液，调整细胞浓度后用裂红液裂解单细胞悬液中的红细胞，用特异性肽池刺激脾脏细胞，使其分泌细胞因子，加入ContainingBrefeldin A分泌阻断剂后阻断分泌，然后经过细胞活死染色，表面受体FcR阻断，CD3、CD45、CD4表面染色，固定破膜和IL-2、IFN-γ胞内染色等步骤后，利用流式细胞仪检测分泌IL-2、IFN-γ的CD4+T和CD8+T细胞的数量，并计算阳性细胞比例，检测数量如图4所示。
Claims (8)
1. 一种含有IL-2和Fc的gE融合蛋白，其特征在于，所述融合蛋白包括水痘-带状疱疹病毒糖蛋白E胞外区段、人白细胞介素2序列和人免疫球蛋白G1的Fc段，所述融合蛋白的氨基酸序列如SEQ ID NO.7所示。
2.一种水痘-带状疱疹疫苗，其特征在于，所述疫苗包括抗原和佐剂，所述抗原为权利要求1所述的含有IL-2和Fc的gE融合蛋白。
3.根据权利要求2所述的水痘-带状疱疹疫苗，其特征在于，所述佐剂为氢氧化铝佐剂、磷酸铝佐剂、含有皂素的中性脂质体佐剂、含有皂素的阳离子脂质体佐剂、含有皂素的阴离子脂质体佐剂、CpG佐剂、纳米乳剂、含有3D-MPL的佐剂中的任意一种或任意多种组合使用。
4.根据权利要求2所述的水痘-带状疱疹疫苗，其特征在于，所述疫苗的每个剂量单位中含有融合蛋白5～200μg。
5.一种根据权利要求2所述的水痘-带状疱疹疫苗的制备方法，其特征在于，包括以下步骤：
S1、培养基因工程化细胞，在基因工程化细胞内表达含有IL-2和Fc的gE融合蛋白，所述基因工程化细胞为CHO细胞；所述融合蛋白的氨基酸序列如SEQ ID NO.7所示；
S2、分离含有IL-2和Fc的gE融合蛋白；
S3、佐剂制备；
S4、疫苗配制。
6.根据权利要求5所述的一种水痘-带状疱疹疫苗的制备方法，其特征在于，所述S1包括：
S11、将编码含有IL-2和Fc的gE融合蛋白的基因克隆入表达载体中；
S12、将S11所得的表达载体转化至基因工程化细胞中；
S13、通过迷你细胞群的筛选和单克隆筛选，获得稳定表达含有IL-2和Fc的gE融合蛋白的细胞株；
S14、使用S13所得的细胞株进行表达，获得含有IL-2和Fc的gE融合蛋白。
7.根据权利要求5所述的一种水痘-带状疱疹疫苗的制备方法，其特征在于，所述CHO细胞为CHO-K1细胞。
8.根据权利要求6所述的一种水痘-带状疱疹疫苗的制备方法，其特征在于，所述表达载体为携带GS筛选系统和/或携带博莱霉素抗性基因的质粒表达载体。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310999194.XA CN117003894B (zh) | 2023-08-09 | 2023-08-09 | 一种含有IL-2和Fc的gE融合蛋白及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310999194.XA CN117003894B (zh) | 2023-08-09 | 2023-08-09 | 一种含有IL-2和Fc的gE融合蛋白及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117003894A CN117003894A (zh) | 2023-11-07 |
| CN117003894B true CN117003894B (zh) | 2024-04-16 |
Family
ID=88566976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310999194.XA Active CN117003894B (zh) | 2023-08-09 | 2023-08-09 | 一种含有IL-2和Fc的gE融合蛋白及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117003894B (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114081943A (zh) * | 2021-11-08 | 2022-02-25 | 中国医学科学院医学生物学研究所 | 一种水痘-带状疱疹mRNA疫苗组合物及其制备方法和应用 |
| CN114767844A (zh) * | 2022-04-28 | 2022-07-22 | 泰州拜奥生物技术有限公司 | 一种水痘-带状疱疹病毒疫苗及其应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3868399A4 (en) * | 2018-09-27 | 2022-07-20 | Bravovax Co., Ltd. | IMMUNE COMPOSITION, METHOD FOR PREPARATION AND ASSOCIATED APPLICATION |
-
2023
- 2023-08-09 CN CN202310999194.XA patent/CN117003894B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114081943A (zh) * | 2021-11-08 | 2022-02-25 | 中国医学科学院医学生物学研究所 | 一种水痘-带状疱疹mRNA疫苗组合物及其制备方法和应用 |
| CN114767844A (zh) * | 2022-04-28 | 2022-07-22 | 泰州拜奥生物技术有限公司 | 一种水痘-带状疱疹病毒疫苗及其应用 |
Non-Patent Citations (2)
| Title |
|---|
| Immunogenicity of a recombinant varicella-zoster virus gE-IE63 fusion protein, a putative vaccine candidate against primary infection and zoster reactivation;Alain Jacquet等;《Vaccine》;20020222;第20卷(第11-12期);第1593-1602页 * |
| 水痘-带状疱疹病毒糖蛋白E胞外域基因的真核细胞稳定表达及其免疫反应性的初步研究;伊兴旭等;《安徽医科大学学报》;20150323;第50卷(第3期);第259-264页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117003894A (zh) | 2023-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114081943B (zh) | 一种水痘-带状疱疹mRNA疫苗组合物及其制备方法和应用 | |
| US20210290759A1 (en) | Immune composition, preparation method therefor, and application thereof | |
| JP7337935B2 (ja) | 組換え水痘帯状疱疹ウイルスワクチン | |
| CN113845576B (zh) | 重组猫疱疹病毒1型gB-gD蛋白及其应用 | |
| WO2023051701A1 (zh) | 抗SARS-CoV-2感染的mRNA、蛋白以及抗SARS-CoV-2感染的疫苗 | |
| CN116327912A (zh) | 带状疱疹疫苗组合物 | |
| CN116747298B (zh) | 一种水痘-带状疱疹病毒疫苗及其制备方法和应用 | |
| CN112142828B (zh) | 一种gE基因及表达该基因的载体 | |
| CN108823245A (zh) | 一种病毒样颗粒的纯化方法 | |
| CN117187265A (zh) | 重组柯萨奇病毒a10 vlp及其用途 | |
| EP2479186A1 (en) | Genes encoding major capsid protein L1 of human papilloma viruses | |
| CN117003894B (zh) | 一种含有IL-2和Fc的gE融合蛋白及其制备方法和应用 | |
| CN117003895B (zh) | 一种含有IL2、Fc和PADRE的gE融合蛋白及其制备方法和应用 | |
| CN117003891B (zh) | 一种含有P2和Fc的gE融合蛋白及其制备方法和应用 | |
| CN115819522B (zh) | 一种带状疱疹病毒疫苗、表达蛋白及重组腺病毒制备与应用 | |
| CN117003893B (zh) | 一种含有IL-2和P2表位的gE融合蛋白及其制备方法和应用 | |
| CN114891072B (zh) | 预防和/或治疗疱疹病毒的截短的疫苗抗原肽及其制备方法和应用 | |
| CN117003895A (zh) | 一种含有IL2、Fc和PADRE的gE融合蛋白及其制备方法和应用 | |
| CN117003892A (zh) | 一种含有PADRE和Fc的gE融合蛋白及其制备方法和应用 | |
| CN117003890A (zh) | 一种含有P2和两个Fc的gE融合蛋白及其制备方法和应用 | |
| CN118085106A (zh) | 一种含有P2、Fc和PADRE的gE融合蛋白及其制备方法和应用 | |
| CN115894707A (zh) | 一种基因重组水痘-带状疱疹病毒融合蛋白及其制备方法和应用 | |
| CN117003896A (zh) | 一种含有P2和PADRE表位的gE融合蛋白及其制备方法和应用 | |
| CN115073565A (zh) | 重组新型冠状病毒s蛋白三聚体及其制备方法与应用 | |
| KR960008674B1 (ko) | 베리셀라-죠스터 바이러스, 이의 생산방법 및 이를 함유하는 백신 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Mou Heping Inventor after: Dong Zhong Inventor after: Liu Silin Inventor after: Tang Yuqin Inventor after: Wan Yu Inventor after: Zhang Qiang Inventor after: Liu Lu Inventor after: Ma Hengjun Inventor after: Fan Fan Inventor after: Request for anonymity Inventor before: Mou Heping Inventor before: Dong Zhong Inventor before: Liu Silin Inventor before: Tang Yuqin Inventor before: Wan Yu Inventor before: Zhang Qiang Inventor before: Liu Lu Inventor before: Fan Shaowen Inventor before: Fan Fan Inventor before: Request for anonymity |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |